Corrigendum to “Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study” [Eur Urol 83 (2023) 15–26, (S0302283822025544), (10.1016/j.eururo.2022.08.005)]
Authors
Evan Y. Yu, Fred Hutchinson Cancer Research Center
Josep M. Piulats, Institute Catala Oncologia
Gwenaelle Gravis, Institut Paoli-Calmettes
Peter C.C. Fong, Auckland City Hospital
Tilman Todenhöfer, Studienpraxis Urologie
Brigitte Laguerre, Centre Eugène Marquis Rennes
Jose A. Arranz, Hospital General Universitario Gregorio Marañon
Stephane Oudard, Hôpital Européen Georges-Pompidou
Christophe Massard, Institut de Cancerologie Gustave Roussy
Julia Heinzelbecker, Universitätsklinikum des Saarlandes Medizinische Fakultät der Universität des Saarlandes
Luke T. Nordquist, Urology Cancer Center and GU Research Network
Joan Carles, Vall d‘Hebron Institut de Oncologia
Michael P. Kolinsky, Cross Cancer Institute
Marinela Augustin, Paracelsus Medical University
Howard Gurney, Macquarie University
Ali Tafreshi, University of Wollongong
Xin Tong Li, Merck & Co., Inc.
Ping Qiu, Merck & Co., Inc.
Christian H. Poehlein, Merck & Co., Inc.
Charles Schloss, Merck & Co., Inc.
Johann S. de Bono, The Institute of Cancer Research
Publication Name
European Urology
Abstract
The authors regret that there was an error in the supplementary files – Table 6. The correct values for ‘Severe skin reaction’ are shown below, and also updated online accordingly. [Table presented] The authors would like to apologise for any inconvenience caused.
Open Access Status
This publication may be available as open access
